查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423622

到 2030 年流感诊断市场预测：按产品类型、最终用户和地区分類的全球分析

Influenza Diagnostics Market Forecasts to 2030 - Global Analysis By Product, Test Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球流感诊断市场规模将达到 23.2 亿美元，预计 2030 年将达到 40.6 亿美元，预测期内复合年增长率为 8.3%。

流感诊断包括识别和确认流感病毒感染的方法。抗原检测等快速检测透过检测呼吸道检体中的病毒蛋白来提供快速结果。聚合酶链反应 (PCR) 等分子测试透过检测病毒的遗传物质提供高灵敏度和特异性。这些方法可以帮助早期诊断并指导适当的治疗和公共卫生干预措施。及时、准确的流感诊断有助于有效的病例管理、疫情控制和疫苗开发。

根据世界卫生组织（WHO）报告，到2023年，每年季节性流感患者人数将达到约10亿人，其中3至500万人病情严重。此外，流感每年导致全球 29 万至 65 万例呼吸道疾病死亡。

流感疫情增加

全球流感发病率的不断上升强调了对高效、快速诊断工具的需求。市场对能够快速准确检测流感病毒的先进诊断技术的需求激增。这种不断增长的需求正在推动创新诊断解决方案的研究和开发，并推动市场扩张。由于医疗保健系统优先考虑流感的早期检测和有效管理，在全球减轻流感流行影响的迫切需求的推动下，流感诊断市场有望持续成长。

敏感性和特异性有限

流感诊断在检测流感病毒方面发挥重要作用，但识别亚型和病毒株的准确性仍然令人担忧。快速进化和抗原变异使诊断设计变得复杂，难以产生假阴性或区分流感亚型。假阳性和假阴性可能导致误诊，影响患者治疗和公共卫生工作。平衡流感诊断的敏感性和特异性之间的权衡仍然是一个复杂的挑战，阻碍了市场的成长。

活性化研究和开发

诊断技术（包括分子和快速检测方法）的不断进步正在提高流感检测的准确性和效率。主要市场参与企业增加的研发投资和政府措施正在推动创新，从而开发出更可靠、更快速的诊断工具。研发活动的活性化不仅促进了技术突破，也为新的诊断解决方案铺平了道路，最终推动市场成长。此外，该领域研究的动态格局被定位为市场扩张的关键驱动力。

与抗病毒药物的竞争

随着製药业的不断进步，抗病毒药物将成为流感的主要治疗方法，从而可能减少对诊断工具的需求。有效抗病毒治疗的可用性可以降低快速且准确诊断解决方案的紧迫性，从而影响市场成长。竞争形势向以治疗为中心的方法的转变凸显了随着流感管理动态的发展不断创新以保持诊断的相关性和竞争力的必要性。

COVID-19 的影响

COVID-19 大流行对流感诊断市场产生了重大影响。人们对呼吸道感染疾病的认识不断提高，由于与新冠病毒症状重迭而对诊断测试的需求不断增加，以及医疗基础设施的激增正在对市场产生积极影响。此外，透过专注于先进的诊断技术和病毒学研究，流感诊断的创新正在不断推进。然而，大流行期间供应链和医疗服务的中断带来了挑战。整体来看，市场正经历动态变化，疫情影响下机会与挑战并存。

预计预测期内血清学检测领域规模最大

血清学检测领域预计将出现良好成长。血清学检测透过检测患者血清中的抗体来帮助识别和监测流感感染，在流感诊断中发挥重要作用。这种方法有助于区分当前和过去的感染，并可以全面了解个体的免疫反应。总体而言，血清学检测的多功能性提高了诊断准确性，为预防策略提供信息，并增强了流感感染的整体管理。

在预测期内，复合年增长率最高的将是临床实验室领域。

预计临床实验室产业在预测期内将经历最高的复合年增长率。在临床实验室中，流感诊断在患者治疗和公共卫生中发挥着至关重要的作用。快速且准确地识别流感病毒可以及时做出治疗决定，并减少疾病的严重程度和持续时间。 PCR 检测和快速抗原检测等诊断检测可实现早期检测，并帮助医护人员实施感染控制措施以防止进一步感染。这些测试将改善患者的治疗结果，支持公共卫生倡议，为疫苗接种策略提供讯息，并确保临床实验室在有效的流感管理和控制中发挥重要作用。

比最大的地区

由于意识的提高、医疗保健支出的增加以及流感病例的激增，亚太地区预计将在预测期内占据最大的市场占有率。在该地区，PCR检测和快速流感检测等先进诊断技术备受关注。此外，政府倡议加上对现场检测需求的不断增长正在推动市场扩张。罗氏诊断公司 (Roche Diagnostics)、雅培实验室 (Abbott Laboratories) 和赛默飞世尔科技 (Thermo Fisher Scientific) 等主要企业正致力于策略联盟和产品创新，以提高其市场占有率。在积极的公共卫生倡议和诊断技术不断进步的推动下，亚太地区流感诊断市场预计将持续成长。

复合年增长率最高的地区：

由于流感流行不断增加以及对准确及时诊断解决方案的持续需求，预计北美在预测期内将呈现最高的复合年增长率。该地区对快速、灵敏的诊断工具的需求强劲，推动了技术进步。 Luminex Corporation、DiaSorin 和 Becton, Dickinson and Company (BD) 等主要企业专注于 PCR 和免疫测量等创新技术，以实现高效流感检测。市场受到政府措施、意识不断提高以及即时检测需求等因素的影响。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球流感诊断市场：按产品

  • 装置
  • 套件和试剂
  • 其他产品

第六章全球流感诊断市场：依测试类型

  • 传统诊断测试
    • 病毒培养
    • 直接萤光抗体测试 (DFAT)
    • 流感快速诊断检验 (RIDT)
  • 分子诊断分析
    • 基于简单扩增的测定 (SAMBA)
    • 基于核酸序列的扩增检验 (NASBAT)
    • 基于恒温环型核酸扩增的测定（LAMP）
    • 逆转录聚合酶连锁反应 (RT-PCR)
  • 血清学检测
    • 血凝抑制 (HI) 测定
    • 微量中和测定
  • 其他测试类型

第七章全球流感诊断市场：依最终使用者分类

  • 即时检测
  • 医院
  • 临床实验室
  • 学术/研究机构
  • 居家照护环境
  • 其他最终用户

第八章全球流感诊断市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Altona Diagnostics GmbH
  • ELITech Group
  • GenMark Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Coris BioConcept
  • DiaSorin SpA
  • Meridian Bioscience Inc.
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fischer Scientific Inc.
  • Hologic Inc.
  • Mast Group
  • Siemens Healthineers AG
  • BioMerieux SA
  • Luminex Corporation
Product Code: SMRC24856

According to Stratistics MRC, the Global Influenza Diagnostics Market is accounted for $2.32 billion in 2023 and is expected to reach $4.06 billion by 2030 growing at a CAGR of 8.3% during the forecast period. Influenza diagnostics involve methods to identify and confirm influenza virus infections. Rapid tests, such as antigen detection assays, provide quick results by detecting viral proteins in respiratory samples. Molecular tests, like polymerase chain reaction (PCR), offer high sensitivity and specificity by detecting viral genetic material. These methods aid in early diagnosis, guiding appropriate treatment and public health interventions. Timely and accurate influenza diagnostics enables effective patient management, outbreak control and vaccine development.

According to the World Health Organization report, in 2023, there were around a billion cases of seasonal influenza annually, including 3-5 million cases of severe illness. Moreover, influenza causes 290,000 to 650,000 respiratory deaths annually around the globe.

Market Dynamics:

Driver:

Rising prevalence of influenza

The increasing incidence of influenza cases worldwide underscores the critical need for efficient and rapid diagnostic tools. The market is witnessing a surge in demand for advanced diagnostic technologies capable of swift and accurate detection of influenza viruses. This heightened demand is steering research and development efforts towards innovative diagnostic solutions, fostering market expansion. As healthcare systems prioritize early detection and effective management of influenza, the influenza diagnostics market is poised to witness sustained growth, driven by the urgent global health imperative to mitigate the impact of influenza outbreaks.

Restraint:

Limited sensitivity & specificity

While influenza diagnostics play a crucial role in detecting influenza viruses, their accuracy in differentiating between subtypes and strains remains a concern. Rapid evolution and antigenic variability challenge the design of diagnostics, leading to false negatives or difficulty in distinguishing between influenza subtypes. False positives and negatives can lead to misdiagnoses, impacting patient care and public health efforts. Balancing the trade-off between sensitivity and specificity remains a complex task in influenza diagnostics, which hinder the market growth.

Opportunity:

Growing research & development activities

Ongoing advancements in diagnostic technologies, such as molecular and rapid testing methods, are enhancing the accuracy and efficiency of influenza detection. Increasing investments in R&D by key market players and government initiatives are driving innovation, leading to the development of more reliable and rapid diagnostic tools. This surge in R&D activities not only fosters technological breakthroughs but also opens avenues for novel diagnostic solutions, ultimately propelling the growth of the market. Also, the dynamic landscape of research in this field positions it as a crucial driver for market expansion.

Threat:

Competition from antiviral medications

As pharmaceutical advancements continue, antiviral drugs gain prominence as a primary intervention for influenza, potentially diminishing the demand for diagnostic tools. The availability of effective antiviral treatments may reduce the urgency for rapid and accurate diagnostic solutions, impacting the market's growth. The healthcare landscape's shift towards treatment-oriented approaches underscores the need for constant innovation in diagnostics to maintain relevance and competitiveness amid the evolving dynamics of influenza management.

Covid-19 Impact

The covid-19 pandemic has significantly influenced the influenza diagnostics market. Increased awareness of respiratory infections, heightened demand for diagnostic testing due to overlapping symptoms with covid, and a surge in healthcare infrastructure have positively impacted the market. Additionally, the focus on advanced diagnostic technologies and research in virology has driven innovation in influenza diagnostics. However, disruptions in the supply chain and healthcare services during the pandemic have presented challenges. Overall, the market has experienced a dynamic shift with both opportunities and obstacles arising from the epidemic impact.

The serological testing segment is expected to be the largest during the forecast period

The serological testing segment is estimated to have a lucrative growth. Serological testing plays a crucial role in Influenza Diagnostics by detecting antibodies in a patient's blood serum, aiding in the identification and monitoring of influenza infections. This method helps differentiate between current and past infections, allowing for a comprehensive understanding of an individual's immune response. Overall, the versatility of serological testing enhances diagnostic accuracy, informs preventative strategies, and strengthens the overall management of influenza infections.

The clinical laboratories segment is expected to have the highest CAGR during the forecast period

The clinical laboratories segment is anticipated to witness the highest CAGR growth during the forecast period. In clinical laboratories, influenza diagnostics play a pivotal role in patient care and public health. Rapid and accurate identification of influenza viruses aids in timely treatment decisions, reducing the severity and duration of illness. Diagnostic tests, including PCR and rapid antigen assays, enable early detection, helping healthcare professionals implement infection control measures to prevent further transmission. These tests enhance patient outcomes, support public health initiatives, and inform vaccination strategies, demonstrating their indispensable role in clinical laboratories for effective influenza management and control.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increased awareness, rising healthcare expenditure, and a surge in influenza cases. Advanced diagnostic technologies, such as PCR and rapid influenza detection tests, are gaining prominence in the region. Additionally, government initiatives coupled with the growing demand for point-of-care testing, are driving market expansion. Key players such as Roche Diagnostics, Abbott Laboratories and Thermo Fisher Scientific are focusing on strategic collaborations and product innovations to strengthen their market presence. The Asia Pacific Influenza Diagnostics Market is poised for continued growth, driven by a proactive approach to public health and the continual evolution of diagnostic technologies.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of influenza and the constant need for accurate and timely diagnostic solutions. The region witnesses a robust demand for rapid and sensitive diagnostic tools, driving technological advancements. Key players in the market like Luminex Corporation, DiaSorin and Becton, Dickinson and Company (BD) focus on innovative techniques like PCR and immunoassays for efficient influenza detection. The market is influenced by factors such as government initiatives, rising awareness, and the need for point-of-care testing.

Key players in the market

Some of the key players profiled in the Influenza Diagnostics Market include Altona Diagnostics GmbH, ELITech Group, GenMark Diagnostics, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Becton, Dickinson, and Company, Coris BioConcept, DiaSorin SpA, Meridian Bioscience Inc., Quidel Corporation, Sekisui Diagnostics, Thermo Fischer Scientific Inc., Hologic Inc., Mast Group, Siemens Healthineers AG, BioMerieux SA and Luminex Corporation.

Key Developments:

In September 2022, Siemens Healthineers released its new CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test. Validated on the company's VERSANT kPCR Molecular System, the kit combines Siemens Healthineers FTD SARS-CoV-23 and FTD Flu/HRSV Assays.

In February 2022, Roche announced the expansion of the COVID-19 PCR portfolio to the cobas® 5800 System, a recently launched molecular laboratory instrument, in countries accepting the CE mark. These include cobas SARS-CoV-2 Qualitative and cobas SARS-CoV-2 & Influenza A/B tests. These launches expand the Roche Diagnostics molecular portfolio offering by providing standardized performance and efficiencies across low, medium and high volume molecular laboratory testing needs.

Products Covered:

  • Instruments
  • Kits & Reagents
  • Other Products

Test Types Covered:

  • Traditional Diagnostic Test
  • Molecular Diagnostic Assay
  • Serological Testing
  • Other Test Types

End Users Covered:

  • Point-of-Care Testing
  • Hospitals
  • Clinical Laboratories
  • Academic/Research Institutes
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Influenza Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Kits & Reagents
  • 5.4 Other Products

6 Global Influenza Diagnostics Market, By Test Type

  • 6.1 Introduction
  • 6.2 Traditional Diagnostic Test
    • 6.2.1 Viral Culture
    • 6.2.2 Direct Fluorescent Antibody Test (DFAT)
    • 6.2.3 Rapid Influenza Diagnostic Test (RIDT)
  • 6.3 Molecular Diagnostic Assay
    • 6.3.1 Simple Amplification-based Assay (SAMBA)
    • 6.3.2 Nucleic Acid Sequence-based Amplification Test (NASBAT)
    • 6.3.3 Loop-mediated Isothermal Amplification-based Assay (LAMP)
    • 6.3.4 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
  • 6.4 Serological Testing
    • 6.4.1 Hemagglutination Inhibition (HI) Assays
    • 6.4.2 Microneutralization Assays
  • 6.5 Other Test Types

7 Global Influenza Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Point-of-Care Testing
  • 7.3 Hospitals
  • 7.4 Clinical Laboratories
  • 7.5 Academic/Research Institutes
  • 7.6 Homecare Settings
  • 7.7 Other End Users

8 Global Influenza Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Altona Diagnostics GmbH
  • 10.2 ELITech Group
  • 10.3 GenMark Diagnostics
  • 10.4 F. Hoffmann-La Roche Ltd
  • 10.5 Abbott Laboratories
  • 10.6 Becton, Dickinson, and Company
  • 10.7 Coris BioConcept
  • 10.8 DiaSorin SpA
  • 10.9 Meridian Bioscience Inc.
  • 10.10 Quidel Corporation
  • 10.11 Sekisui Diagnostics
  • 10.12 Thermo Fischer Scientific Inc.
  • 10.13 Hologic Inc.
  • 10.14 Mast Group
  • 10.15 Siemens Healthineers AG
  • 10.16 BioMerieux SA
  • 10.17 Luminex Corporation

List of Tables

  • Table 1 Global Influenza Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Influenza Diagnostics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Influenza Diagnostics Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 4 Global Influenza Diagnostics Market Outlook, By Kits & Reagents (2021-2030) ($MN)
  • Table 5 Global Influenza Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 6 Global Influenza Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 7 Global Influenza Diagnostics Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 8 Global Influenza Diagnostics Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 9 Global Influenza Diagnostics Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 10 Global Influenza Diagnostics Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 11 Global Influenza Diagnostics Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 12 Global Influenza Diagnostics Market Outlook, By Simple Amplification-based Assay (SAMBA) (2021-2030) ($MN)
  • Table 13 Global Influenza Diagnostics Market Outlook, By Nucleic Acid Sequence-based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 14 Global Influenza Diagnostics Market Outlook, By Loop-mediated Isothermal Amplification-based Assay (LAMP) (2021-2030) ($MN)
  • Table 15 Global Influenza Diagnostics Market Outlook, By Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) (2021-2030) ($MN)
  • Table 16 Global Influenza Diagnostics Market Outlook, By Serological Testing (2021-2030) ($MN)
  • Table 17 Global Influenza Diagnostics Market Outlook, By Hemagglutination Inhibition (HI) Assays (2021-2030) ($MN)
  • Table 18 Global Influenza Diagnostics Market Outlook, By Microneutralization Assays (2021-2030) ($MN)
  • Table 19 Global Influenza Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 20 Global Influenza Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Influenza Diagnostics Market Outlook, By Point-of-Care Testing (2021-2030) ($MN)
  • Table 22 Global Influenza Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Influenza Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 24 Global Influenza Diagnostics Market Outlook, By Academic/Research Institutes (2021-2030) ($MN)
  • Table 25 Global Influenza Diagnostics Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 26 Global Influenza Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.